Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Hepatocyte Growth Factor (HGF) in Patients With Acute Coronary Syndrome (ACS)
Launched by NATIONAL INSTITUTE OF CARDIOLOGY, WARSAW, POLAND · Feb 13, 2009
Trial Information
Current as of June 15, 2025
Completed
Keywords
ClinConnect Summary
In the recent years several biomarkers have been investigated to be used for diagnostic and risk stratification in patients with symptoms of acute coronary syndrome. Troponins are preferred markers for myocardial injury due to its high specificity and sensitivity what makes them superior than traditional cardiac enzymes as CK or CK-MB. Elevated level of NT-proBNP is a marker of heart failure strongly associated with increased mortality rate. This study is invented for searching new sensitive indicators of myocardial injury and predictors of bad outcome in patients with symptoms of ACS espec...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. typical chest pain;
- • 2. ST segment elevation or depression in ECG;
- • 3. indication for coronary angiography; if necessary with PCI and 4) signed inform consent.
- Exclusion Criteria:
- • 1. known past history of a myocardial infarction;
- • 2. not signed informed consent.
About National Institute Of Cardiology, Warsaw, Poland
The National Institute of Cardiology in Warsaw, Poland, is a leading research institution dedicated to advancing the understanding and treatment of cardiovascular diseases. Renowned for its commitment to innovative clinical research, the Institute focuses on improving patient outcomes through comprehensive studies that encompass prevention, diagnosis, and therapeutic strategies. With a multidisciplinary team of experts and state-of-the-art facilities, the National Institute of Cardiology plays a pivotal role in contributing to global cardiovascular knowledge and enhancing clinical practices in the field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warsaw, , Poland
Patients applied
Trial Officials
Anna Konopka, PhD
Study Director
Institute of Cardiology, CCU
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials